Company Overview
Snapshot
Founded in March 2014 by Iftach Dolev and Hilla Fogel, QuantalX NeuroScience operates with 11–50 employees. The company has raised $8.6 million across four funding rounds and received FDA De Novo authorization for its Delphi-MD system in November 2025.
Business overview
QuantalX NeuroScience is a Health Tech & Life Sciences company focused on making brain health accessible through its core product, Delphi-MD. This FDA De Novo–authorized device utilizes Direct Electrophysiological Imaging technology to map brain activity, providing real-time functional responses. The technology serves various healthcare markets by offering non-invasive brain health insights for clinicians across a wide range of care settings, operating within the Medical Devices and Digital Healthcare sectors.
Strategic signal
QuantalX NeuroScience achieved a significant milestone in November 2025 by receiving FDA De Novo authorization for its Delphi-MD system. This clearance establishes a new modality for brain function assessment, validating the company's innovative approach to neuro-imaging and enabling commercial deployment in the US and Europe. This signals strong regulatory validation and market readiness, positioning QuantalX for substantial growth and broader adoption of its technology in clinical practice.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory achievement for QuantalX NeuroScience in late 2025?
- In November 2025, QuantalX NeuroScience received FDA De Novo clearance for its Delphi-MD System, establishing a new modality for brain function assessment and enabling its use in clinical practice.
- What was a significant European market entry milestone for QuantalX NeuroScience?
- In February 2025, QuantalX Neuroscience Ltd. announced that its Delphi-MD neurodiagnosis medical device received CE MDR approval, facilitating its commercialization across Europe.
- What breakthrough did QuantalX NeuroScience announce regarding Parkinson's disease in October 2024?
- In October 2024, QuantalX Neuroscience announced a significant breakthrough in the early diagnosis and subtyping of Parkinson’s disease using its Delphi-MD device, published in npj Parkinson’s Disease by Nature Magazine.
- Which US university did QuantalX NeuroScience partner with in June 2024?
- In June 2024, QuantalX Neuroscience Ltd. partnered with the Department of Neurology and Rehabilitation at the University of Illinois Chicago to commercialize its Delphi-MD technology in the US through groundbreaking studies.
- What strategic program did QuantalX NeuroScience join with the FDA in April 2024?
- In April 2024, QuantalX Neuroscience was selected by the FDA for the Total Life Cycle Advisory Program (TAP), aimed at advancing the Delphi-MD medical device for early detection of Normal Pressure Hydrocephalus.